Loading company…
TXINNO Bioscience researches and manufactures molecular immuno-oncology drugs.
TXINNO Bioscience researches and manufactures molecular immuno-oncology drugs, using AI to develop enzyme inhibitors and therapies that activate innate immunity. Founded in 2020, it is based in Yongin, South Korea, and is at Series B stage. In March 2023, it raised KRW 2 billion from Korea Venture Investment Corporation and Hyundai Pharm.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in